(Q48785648)

15 February 2018

title

Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS. (English)

1 reference

15 February 2018

author name string

Wu X

1

1 reference

15 February 2018

Dastidar P

2

1 reference

15 February 2018

Kuusisto H

3

1 reference

15 February 2018

Ukkonen M

4

1 reference

15 February 2018

Huhtala H

5

1 reference

15 February 2018

Elovaara I

6

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 October 2005

1 reference

15 February 2018

Acta Neurologica Scandinavica

published in

1 reference

15 February 2018

volume

112

1 reference

15 February 2018

issue

4

1 reference

15 February 2018

page(s)

242-247

1 reference

15 February 2018

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00477.X

10.1111/J.1600-0404.2005.00477.X

21 January 2018

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018